Primary Aldosteronism in Patients in China With Recently Detected Hypertension.
Zhixin Xu, Jun Yang, Jinbo Hu...
https://pubmed.ncbi.nlm.nih.gov/32327102/Actively Recruiting
Led by Qifu Li · Updated on 2026-04-06
8000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying endocrine and metabolic diseases by creating a specialized database called the Chongqing Environment, Inflammation, and Metabolic Diseases Study EIMDS. This observational study aims to build an early warning model based on environmental, genetic, and protein factors to uncover new mechanisms behind these diseases and identify new treatment targets. The cohort includes about 8,000 community members followed for over five years. Participants are grouped based on having hypertension, diabetes mellitus, or autonomous aldosterone secretion AAS. The study involves baseline biochemical screenings, including tests measuring plasma aldosterone and renin levels to classify AAS. No experimental treatments are given instead, participants continue their usual clinical care while undergoing standardized assessments and biospecimen collections for advanced molecular analyses. During the study, participants undergo clinical, biochemical, and event assessments every two years, with blood and urine samples collected for research. The primary outcome is to determine the prevalence of AAS over a five-year follow-up. Secondary outcomes include identifying risk factors, exploring associations between AAS and kidney or metabolic disorders, and screening for key proteins and biomarkers. The study helps understand disease progression through detailed molecular and clinical data gathered over time.
CONDITIONS
Environment, Inflammation and Metabolic Diseases Study
Q
Qifu Li, MD, PhD, Chief Physician
S
Shumin Yang, MD, PhD, Chief Physician
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Qifu Li
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo baseline biochemical screening and standardized assessments including measurement of plasma aldosterone concentration, plasma renin concentration, and collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.
1 visit (in-person)
Duration - Approximately 5 years
Participants are followed up every two years for clinical, biochemical, and endpoint event assessments, including collection of blood and urine samples to explore risk factors and molecular mechanisms of endocrine and metabolic diseases.
Assessments every 2 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Zhixin Xu, Jun Yang, Jinbo Hu...
https://pubmed.ncbi.nlm.nih.gov/32327102/Frank B Hu, Ambika Satija, JoAnn E Manson
https://pubmed.ncbi.nlm.nih.gov/25996138/Xiaolong Guo, Zhichun Zhang, Ting Zeng...
https://pubmed.ncbi.nlm.nih.gov/31327757/Paolo Mulatero, Silvia Monticone, Jacopo Burrello...
https://pubmed.ncbi.nlm.nih.gov/27607462/Ying Bao, Jiali Han, Frank B Hu...
https://pubmed.ncbi.nlm.nih.gov/24256379/Sylvia H Ley, Osama Hamdy, Viswanathan Mohan...
https://pubmed.ncbi.nlm.nih.gov/24910231/Peter Arner, Agné Kulyté
https://pubmed.ncbi.nlm.nih.gov/25732520/Deirdre K Tobias, An Pan, Chandra L Jackson...
https://pubmed.ncbi.nlm.nih.gov/24428469/Jinbo Hu, Shumin Yang, Aipin Zhang...
https://pubmed.ncbi.nlm.nih.gov/27538755/Juliana C N Chan, Vasanti Malik, Weiping Jia...
https://pubmed.ncbi.nlm.nih.gov/19470990/Qifu Li
Lead Sponsor